01
Cash & equivalents decreased 28.4%
Cash & equivalents changed -28.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
$152.9M→$109.5MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTXBiotech Inc.'s latest supported as-filed period reports interest income of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -28.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Net income changed -283.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed +3.0% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
XBIT · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001171843-26-005492SEC ↗10-QMay 14, 2026Period Mar 31, 20260001171843-26-003419SEC ↗10-K/AApr 29, 2026Period Dec 31, 20250001171843-26-002814SEC ↗10-KMar 13, 2026Period Dec 31, 20250001171843-26-001561SEC ↗8-KDec 9, 2025Period Dec 5, 20250001171843-25-007836SEC ↗10-QNov 12, 2025Period Sep 30, 20250001171843-25-007233SEC ↗4Nov 12, 2025Period Oct 1, 20250001193125-25-276344SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 1, 2025Filed Nov 12, 2025 | Rademaker Craig EvanDirector | Grant Or AwardDirect | 92,104 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -0.7% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Stock-based compensation changed +60.7% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-25-276340